TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9988955

Group type: EXPERIMENTAL
Intervention: Early invasive management (diagnostic angiography within 2 to 3 days, followed by revascularization if indicated)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative management (radionuclide ventriculography and thallium stress testing as initial diagnostic tests)
Number of subjects: 0
Study: 8583374

Group type: EXPERIMENTAL
Intervention: Sho‐saiko‐To
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Saiboku‐To
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sairei‐To
Number of subjects: 0
Study: 2182241

Group type: EXPERIMENTAL
Intervention: 30 U of anistreplase (APSAC)
Number of subjects: 156
Study: 535405

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol 100 mg
Number of subjects: 0
Study: 31673898

Group type: EXPERIMENTAL
Intervention: Carfilzomib in combination with lenalidomide and dexamethasone (KRd)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lenalidomide and dexamethasone (Rd)
Number of subjects: 0
Study: 30109404

Group type: EXPERIMENTAL
Intervention: 4-ml autologous adipose-derived stromal vascular fraction (SVF) treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: 4-ml hyaluronic acid treatment
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: SVF treatment
Number of subjects: 16
Study: 29066605

Group type: EXPERIMENTAL
Intervention: Electronic exams (E)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Paper exams (P)
Number of subjects: 145
Study: 26381201

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Microflare only
Number of subjects: 145
Study: 24800919

Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine liquid formulation
Number of subjects: 20

Group type: COMPARATOR
Intervention: 6-mercaptopurine capsules
Number of subjects: 20
Study: 21431414

Group type: EXPERIMENTAL
Intervention: Combined peer and managerial intervention
Number of subjects: 1382

Group type: EXPERIMENTAL
Intervention: Peer education
Number of subjects: 1382

Group type: EXPERIMENTAL
Intervention: Managerial training
Number of subjects: 1382

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 1382

Group type: EXPERIMENTAL
Intervention: Establishments with condom use rules
Number of subjects: 1382
Study: 18751689

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily (40QD)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg twice daily (20TD)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Esomeprazole 10 mg 4 times daily (10Q4D)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 17900462

Group type: EXPERIMENTAL
Intervention: Carotid arterial intima‐medial thickness (IMT)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Aortofemoral pulse wave velocity (PWV[a‐f])
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Systemic arterial compliance (SAC)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Carotid‐derived augmentation index
Number of subjects: 315
Study: 15006018

Group type: EXPERIMENTAL
Intervention: budesonide/formoterol adjustable maintenance dosing (AMD)
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: budesonide/formoterol AMD
Number of subjects: 658

Group type: COMPARATOR
Intervention: budesonide/formoterol FD
Number of subjects: 658

Group type: COMPARATOR
Intervention: salmeterol/fluticasone FD
Number of subjects: 658
Study: 11148482

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 9671904

Group type: EXPERIMENTAL
Intervention: Pulmonary vein ligation first
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Pulmonary artery ligation first
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (healthy subjects and patients with interstitial pulmonary fibrosis)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Small-cell lung cancer patients
Number of subjects: 46
Study: 8030598

Group type: EXPERIMENTAL
Intervention: Diet devoid of proline (group 1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Diet devoid of proline, arginine, aspartate, glutamate, and serine (group 2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Complete L-amino acid mixture diet (group 3)
Number of subjects: 20
Study: 31407937

Group type: EXPERIMENTAL
Intervention: Learning to BREATHE (L2B)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Interpersonal Therapy‐Adolescent Skills Training
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Preference for L2B
Number of subjects: 111

Group type: COMPARATOR
Intervention: Preference condition (preference vs. random)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Baseline program preference
Number of subjects: 111
Study: 31508704

Group type: EXPERIMENTAL
Intervention: Universal adhesive with laser etching
Number of subjects: 84

Group type: COMPARATOR
Intervention: Transbond XT with acid etching
Number of subjects: 84

Group type: COMPARATOR
Intervention: Transbond XT with laser etching
Number of subjects: 84

Group type: COMPARATOR
Intervention: Universal adhesive in self-etch mode
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Universal adhesive with acid etching (5, 10, 15 s)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Universal adhesive with three different etching times
Number of subjects: 84
Study: 28225835

Group type: EXPERIMENTAL
Intervention: Half dose of mulberry-extract (Reducose)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Normal dose of mulberry-extract (Reducose)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Double dose of mulberry-extract (Reducose)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 26436182

Group type: COMPARATOR
Intervention: Proximity to alcohol outlets for drinkers (0.18 +/- 0.15 miles)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Density of alcohol outlets within a 1-mile radius for drinkers (153 +/- 47)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Number of alcohol outlets at distances of 0.10-0.25 miles for drinkers (19 +/- 19)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Number of alcohol outlets at distances of 0.25-0.50 miles for drinkers (43 +/- 25)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Proximity and density of alcohol outlets
Number of subjects: 166
Study: 25072523

Group type: EXPERIMENTAL
Intervention: Qigong (Chaoyi Fanhuan qigong [CFQ]) practiced 45 min/day for 8 weeks
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Qigong (level 2 CFQ) in extension trial
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Qigong (initial 8 weeks)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Qigong (narratives from RCT)
Number of subjects: 73
Study: 21947819

Group type: EXPERIMENTAL
Intervention: Abolition centralization, reduction centralization, unstable centralization
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Peripheralization
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: No effect
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Centralization groups (abolition, reduction, unstable)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Centralization and peripheralization
Number of subjects: 176
Study: 19306199

Group type: EXPERIMENTAL
Intervention: Internet version of SF-36
Number of subjects: 782

Group type: COMPARATOR
Intervention: Pen-and-paper version of SF-36
Number of subjects: 782
Study: 16884135

Group type: EXPERIMENTAL
Intervention: PNP (Pediatric Nurse Practitioners)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Resident care
Number of subjects: 65
Study: 15256423

Group type: EXPERIMENTAL
Intervention: Early allogeneic bone marrow transplantation (alloBMT) after 2 consolidation courses
Number of subjects: 198

Group type: COMPARATOR
Intervention: Delayed unpurged autologous stem cell transplantation (ASCT) after 1 additional reinduction
Number of subjects: 198

Group type: COMPARATOR
Intervention: Randomized interferon-alpha maintenance
Number of subjects: 198
Study: 11387538

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patches
Number of subjects: 3575
Study: 9281301

Group type: EXPERIMENTAL
Intervention: New isosorbide dinitrate tablet formulation (5 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Reference preparation of isosorbide dinitrate
Number of subjects: 18
Study: 8103611

Group type: EXPERIMENTAL
Intervention: Oral sotalol treatment (pre- and postoperative)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Routine beta-blocking treatment (half the preoperative dose)
Number of subjects: 101
Study: 3029592

Group type: EXPERIMENTAL
Intervention: Initial radiotherapy plus chemotherapy
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Delayed radiotherapy plus chemotherapy
Number of subjects: 399

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 399
Study: 30737932

Group type: EXPERIMENTAL
Intervention: Endodontic treatment with good quality root filling and good quality crown restoration (GE + GR)
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Endodontic treatment with good quality root filling and poor quality crown restoration (GE + PR)
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Endodontic treatment with poor quality root filling and good quality crown restoration (PE + GR)
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Endodontic treatment with poor quality root filling and poor quality crown restoration (PE + PR)
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Endodontic treatment with root posts
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Endodontic treatment without root posts
Number of subjects: 1001
Study: 27113485

Group type: EXPERIMENTAL
Intervention: PF‐00489791 (20 mg)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study: 24168514

Group type: EXPERIMENTAL
Intervention: Low-dose oral isotretinoin (ISO), 20 mg/day for six months
Number of subjects: 24

Group type: COMPARATOR
Intervention: 0.05% topical retinoic acid (RA) cream for six months
Number of subjects: 24
Study: 22123685

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (LPV/r)
Number of subjects: 445

Group type: COMPARATOR
Intervention: nevirapine (NVP)
Number of subjects: 445
Study: 20695687

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 18343261

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Infliximab 10 mg/kg
Number of subjects: 728

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 728
Study: 16299878

Group type: EXPERIMENTAL
Intervention: Bathing at 60 min postpartum (n = 126)
Number of subjects: 249

Group type: COMPARATOR
Intervention: No bathing (n = 123)
Number of subjects: 249
Study: 12572927

Group type: EXPERIMENTAL
Intervention: 15 mg/kg of intravenous L-carnitine at the end of each hemodialysis treatment (Group A)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 53
Study: 10601747

Group type: EXPERIMENTAL
Intervention: Discourse-dependent semantic anomalies (e.g., 'slow')
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coherent control words (e.g., 'quick')
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anomalous words in single sentences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Words previously anomalous in discourse
Number of subjects: 0
Study: 8521118

Group type: EXPERIMENTAL
Intervention: Untreated patients with DH
Number of subjects: 10

Group type: COMPARATOR
Intervention: Patients with DH on a long-term GFD
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Untreated patients with DH after adhering to GFD for 3 months
Number of subjects: 10

Group type: COMPARATOR
Intervention: Healthy control subjects on an ordinary diet
Number of subjects: 10
Study: 1824560

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide + methotrexate + 5-fluorouracil
Number of subjects: 1034

Group type: COMPARATOR
Intervention: No systemic treatment
Number of subjects: 1034
Study: 7025639

Group type: EXPERIMENTAL
Intervention: Symptothermal method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ovulation method
Number of subjects: 0
Study: 30969260

Group type: EXPERIMENTAL
Intervention: Asfotase alfa (daily subcutaneous injections)
Number of subjects: 7

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 7
Study: 29716784

Group type: EXPERIMENTAL
Intervention: Emixustat 2.5 mg
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Emixustat 5 mg
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Emixustat 10 mg
Number of subjects: 508

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Emixustat (all doses combined)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Emixustat
Number of subjects: 508
Study: 26360658

Group type: EXPERIMENTAL
Intervention: Sodium Picosulphate (NaPico)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Polyethylene Glycol (PEG)
Number of subjects: 72
Study: 24249695

Group type: EXPERIMENTAL
Intervention: Early frenotomy intervention group
Number of subjects: 107

Group type: COMPARATOR
Intervention: Standard care comparison group
Number of subjects: 107
Study: 22353582

Group type: EXPERIMENTAL
Intervention: Burst TENS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham TENS
Number of subjects: 0
Study: 19641360

Group type: EXPERIMENTAL
Intervention: TURIS (transurethral resection in saline)
Number of subjects: 40

Group type: COMPARATOR
Intervention: TURP (traditional monopolar resection)
Number of subjects: 40
Study: 17469136

Group type: EXPERIMENTAL
Intervention: Engagement of beta1 integrin on T cells from patients with active SLE
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transfection of dominant-negative truncations of FAK or WT PTEN
Number of subjects: 0
Study: 15503656

Group type: EXPERIMENTAL
Intervention: ETC-588 (Pfizer)
Number of subjects: 0
Study: 11521333

Group type: EXPERIMENTAL
Intervention: Biphasic electrical conversion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monophasic electrical conversion
Number of subjects: 0
Study: 9394172

Group type: EXPERIMENTAL
Intervention: Standard treatment plus exposure to pulsed magnetic fields (PMF) for four weeks (sinusoidal form, 0.95 to 1.05 Hz, amplitude +/- 2400 nano Teslas)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Standard treatment plus exposure to pulsed magnetic fields (PMF)
Number of subjects: 20
Study: 7515300

Group type: EXPERIMENTAL
Intervention: G‐CSF at a daily dose of 50 micrograms/m2 subcutaneously
Number of subjects: 20

Group type: COMPARATOR
Intervention: No G‐CSF (Control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: G‐CSF
Number of subjects: 20
Study: 2895435

Group type: EXPERIMENTAL
Intervention: Benzodiazepines (greater than 2 mg lorazepam equivalents daily)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Benzodiazepines (less than 2 mg lorazepam equivalents daily)
Number of subjects: 17
Study: 31665874

Group type: COMPARATOR
Intervention: Supervised training
Number of subjects: 17

Group type: COMPARATOR
Intervention: Home-based training
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Total sample (both groups)
Number of subjects: 17
Study: 29411716

Group type: EXPERIMENTAL
Intervention: Colored zirconia (A3)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Colored zirconia (D4)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (non-colored zirconia)
Number of subjects: 72
Study: 26921523

Group type: EXPERIMENTAL
Intervention: Coping and Caring for infants with special needs (COPCA)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Traditional Infant Physiotherapy (TIP)
Number of subjects: 46
Study: 25117466

Group type: EXPERIMENTAL
Intervention: 10-week aerobic training
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (non-training)
Number of subjects: 9
Study: 22978771

Group type: EXPERIMENTAL
Intervention: Quetiapine (750 mg/day)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Risperidone (4 mg/day)
Number of subjects: 119
Study: 20162509

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid for 3 weeks (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No treatment for 3 weeks (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (healthy women with euthyroid status)
Number of subjects: 40
Study: 18019394

Group type: EXPERIMENTAL
Intervention: Low-protein products for renal patients (LPP)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Free low-protein diet (NO-LPP)
Number of subjects: 6
Study: 16142551

Group type: EXPERIMENTAL
Intervention: Extended-release oxybutynin chloride 10 mg/day
Number of subjects: 790

Group type: COMPARATOR
Intervention: Extended-release tolterodine tartrate 4 mg/day
Number of subjects: 790
Study: 12905664

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0
Study: 10484220

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 25

Group type: COMPARATOR
Intervention: Weight-bearing position
Number of subjects: 25
Study: 8949620

Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg and caffeine 50 mg
Number of subjects: 124

Group type: COMPARATOR
Intervention: Paracetamol 400 mg and dextropropoxyphene 30 mg
Number of subjects: 124
Study: 1957847

Group type: EXPERIMENTAL
Intervention: Pipelle biopsy
Number of subjects: 275

Group type: COMPARATOR
Intervention: Novak biopsy
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 275
Study: 7178369

Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg i.v.)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg i.v.) plus Phentolamine (60 mg i.v.)
Number of subjects: 6
Study: 30878234

Group type: EXPERIMENTAL
Intervention: Polymer-free DES
Number of subjects: 326

Group type: COMPARATOR
Intervention: Durable polymer DES
Number of subjects: 326
Study: 31735178

Group type: EXPERIMENTAL
Intervention: Temporal fascia graft plus platelet-rich fibrin therapy
Number of subjects: 91

Group type: COMPARATOR
Intervention: Temporal fascia graft alone
Number of subjects: 91
Study: 27001374

Group type: EXPERIMENTAL
Intervention: Immediate loading of two implants supporting mandibular overdentures (T2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Immediate loading of two implants supporting mandibular overdentures (T3)
Number of subjects: 30
Study: 26023213

Group type: EXPERIMENTAL
Intervention: 8‐week Internet‐based pain coping skills training (PCST) protocol in addition to a 24‐week standardized intervention comprising an 8‐week Internet‐based education package followed by 5 individual physical therapy exercise sessions plus home exercises (3 times weekly)
Number of subjects: 142

Group type: COMPARATOR
Intervention: 24‐week standardized intervention comprising an 8‐week Internet‐based education package followed by 5 individual physical therapy exercise sessions plus home exercises (3 times weekly)
Number of subjects: 142
Study: 24029300

Group type: EXPERIMENTAL
Intervention: Pain Coping Skills Training (PCST)
Number of subjects: 8
Study: 22673937

Group type: EXPERIMENTAL
Intervention: DHR (12 × 5min bouts, 10% decline at 85% VO(2)max)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (non-exercising)
Number of subjects: 10
Study: 20043830

Group type: EXPERIMENTAL
Intervention: Community-tailored education and distribution of LLINs (1 or 2 per household)
Number of subjects: 132
Study: 17634479

Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment in EGFR low group (n = 113)
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment in EGFR high group (n = 73)
Number of subjects: 564

Group type: COMPARATOR
Intervention: Untreated EGFR low group
Number of subjects: 564
Study: 15561731

Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 10845

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10845
Study: 11754853

Group type: COMPARATOR
Intervention: Posterior mediastinal route
Number of subjects: 6
Study: 9679845

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate powder (50 microg or 100 microg twice daily)
Number of subjects: 437

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 437
Study: 8210253

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) administered by drip infusion for 2 hours (group A)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) administered by bolus injection (group B)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Comparison of gastrointestinal toxicity
Number of subjects: 41

Group type: COMPARATOR
Intervention: Leukocytopenia severity
Number of subjects: 41

Group type: COMPARATOR
Intervention: Alopecia frequency
Number of subjects: 41
Study: 3513884

Group type: EXPERIMENTAL
Intervention: Amitriptyline 250 mg for four weeks
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Imipramine 250 mg for four weeks
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 2
Study: 30094517

Group type: EXPERIMENTAL
Intervention: Intracortical facilitation (ICF) using 110% intensity of the test stimulus (TS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Short intracortical inhibition (SICI)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Long intracortical inhibition (LICI)
Number of subjects: 48
Study: 27250831

Group type: EXPERIMENTAL
Intervention: Pilates exercise program with voluntary pelvic floor muscle contraction (PFMC)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Pilates exercise program without voluntary pelvic floor muscle contraction (PFMC)
Number of subjects: 57
Study: 25170796

Group type: EXPERIMENTAL
Intervention: Trospium 30 mg/day + Solifenacin 10 mg/day
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Trospium 15 mg/day + Solifenacin 5 mg/day
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study: 22398088

Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg weekly + Calcium (500 mg) + Vitamin D (400 IU)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo + Calcium (500 mg) + Vitamin D (400 IU)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Risedronate + Calcium + Vitamin D
Number of subjects: 88
Study: 20196149

Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) therapy at a dosage of 5 mg/kg intravenously at weeks 0, 2, 6, and every 8 weeks thereafter
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) therapy
Number of subjects: 40